Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.61 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | GBA2 | Q9HCG7 | 7/20 | 0.49 |
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | UGCG | Q16739 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | AGL | P35573 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11929539 | 1.00 | SPHK2 (0.61) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL11929540 | 1.00 | SPHK2 (0.61) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL23777202 | 0.94 | SPHK2 (0.56) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL4383140 | 0.94 | SPHK2 (0.64) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL7367083 | 0.94 | SPHK2 (0.56) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL20330675 | 0.94 | SPHK2 (0.64) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| Hydrochloric Acid SCHEMBL27684543 | 0.93 | SPHK2 (0.55) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL19223769 | 0.93 | SPHK2 (0.67) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL7270850 | 0.89 | SPHK2 (0.58) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL23866033 | 0.89 | SPHK2 (0.58) | SPHK2SPHK1S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-2448956-B1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NAT RECH SCIENT (FR) | 2018-05-16 | — | — | EP | disclosed |
| EP-2334646-A2 | SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| US-7777041-B2 | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2010-08-17 | — | — | US | disclosed |
| WO-2010033543-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20090156574-A1 | 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | US | disclosed |
| US-7504511-B2 | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-4906634-A | Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as cardiovascular agents | SCHERING A.G. (DE) | 1990-03-06 | — | — | US | disclosed |
| EP-0332570-A2 | Novel-N-(4-(Aminosubstituted)phenyl) methanesulfonamides and their use as cardiovascular agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | TP53, MDM2, TP53BP1 | SPHK2 3251/4885SPHK1 3965/4885S1PR1 4225/4885 |
| US-20090156574-A1 | 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | PAH, ABAT, AADAT | SPHK2 2527/4885SPHK1 3207/4885S1PR1 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.